Savara Inc (NASDAQ:SVRA) Director David A. Ramsay Acquires 25,005 Shares of Stock

Savara Inc (NASDAQ:SVRAGet Rating) Director David A. Ramsay bought 25,005 shares of the stock in a transaction dated Monday, November 21st. The stock was purchased at an average cost of $1.42 per share, for a total transaction of $35,507.10. Following the acquisition, the director now owns 1,926,147 shares in the company, valued at approximately $2,735,128.74. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Savara Stock Up 4.4 %

Shares of NASDAQ SVRA opened at $1.43 on Tuesday. The firm’s 50-day simple moving average is $1.31 and its 200 day simple moving average is $1.45. The company has a market cap of $163.08 million, a price-to-earnings ratio of -5.72 and a beta of 0.67. The company has a quick ratio of 26.55, a current ratio of 26.55 and a debt-to-equity ratio of 0.22. Savara Inc has a 12-month low of $1.02 and a 12-month high of $1.91.

Savara (NASDAQ:SVRAGet Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). On average, research analysts expect that Savara Inc will post -0.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in Savara during the 3rd quarter worth about $26,000. Renaissance Technologies LLC lifted its position in Savara by 235.3% during the 2nd quarter. Renaissance Technologies LLC now owns 56,000 shares of the company’s stock valued at $85,000 after purchasing an additional 39,300 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in Savara by 6.9% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 144,432 shares of the company’s stock valued at $220,000 after purchasing an additional 9,363 shares during the period. Millennium Management LLC lifted its position in Savara by 12.3% during the 2nd quarter. Millennium Management LLC now owns 156,314 shares of the company’s stock valued at $238,000 after purchasing an additional 17,093 shares during the period. Finally, State Street Corp lifted its position in Savara by 12.4% during the 1st quarter. State Street Corp now owns 271,611 shares of the company’s stock valued at $356,000 after purchasing an additional 30,062 shares during the period. Institutional investors and hedge funds own 67.69% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Savara in a report on Monday, November 14th.

About Savara

(Get Rating)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Featured Articles

Insider Buying and Selling by Quarter for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.